Table 3.

IFLs in PL and urine in the placebo and intervention groups and correlations with compliance to study product

Isoflavone valuesIsoflavone values vs study product doses*
PlaceboSoyPPlaceboSoy
BaselineEndBaselineEndBaselineEndrPrP
PL
    DE62 ± 13179 ± 24952 ± 113400 ± 5100.78<0.00010.110.210.40<0.0001
    GE63 ± 16164 ± 15153 ± 103517 ± 5770.11<0.00010.040.620.44<0.0001
    GLYE5.2 ± 128.4 ± 325.8 ± 1116 ± 290.93<0.00010.150.070.37<0.0001
    EQ13 ± 5525 ± 729.8 ± 24129 ± 2320.250.00080.030.700.170.03
    DMA22 ± 5931 ± 6423 ± 70214 ± 2830.70<0.00010.130.110.310.0001
    DHDE23 ± 7538 ± 18418 ± 43120 ± 2240.76<0.00010.100.230.300.0001
    DHGE6.8 ± 3014 ± 1005.8 ± 1627 ± 880.71<0.00010.080.310.210.009
OU§
    DE4.2 ± 9.63.8 ± 9.23.7 ± 7.725 ± 250.45<0.0001−0.030.740.46<0.0001
    GE1.6 ± 5.71.5 ± 5.21.4 ± 3.013 ± 140.22<0.00010.010.940.47<0.0001
    GLYE0.6 ± 1.50.5 ± 1.20.5 ± 1.02.3 ± 2.60.34<0.0001−0.040.640.45<0.0001
    EQ0.9 ± 5.11.4 ± 6.00.5 ± 1.79.6 ± 180.770.21−0.120.130.160.05
    DMA1.4 ± 3.01.1 ± 3.01.4 ± 3.412 ± 130.57<0.00010.000.960.34<0.0001
    DHDE2.3 ± 6.91.7 ± 4.91.8 ± 4.011 ± 140.69<0.00010.000.970.320.0001
    DHGE0.9 ± 4.60.6 ± 2.40.8 ± 2.83.9 ± 9.30.10<0.00010.020.810.230.004
SU
    DE3.3 ± 9.45 ± 153.0 ± 6.716 ± 200.36<0.0001−0.100.220.47<0.0001
    GE1.3 ± 3.82.7 ± 131.2 ± 3.08.0 ± 9.70.23<0.0001−0.060.450.45<0.0001
    GLYE0.4 ± 1.30.4 ± 1.00.4 ± 1.51.2 ± 1.60.51<0.0001−0.050.520.40<0.0001
    EQ0.6 ± 3.91.3 ± 6.30.6 ± 2.410 ± 210.250.02−0.110.190.170.03
    DMA1.5 ± 3.82.3 ± 6.91.7 ± 4.011 ± 120.61<0.0001−0.030.690.35<0.0001
    DHDE1.8 ± 4.93.2 ± 132.1 ± 4.89.7 ± 140.40<0.0001−0.050.520.35<0.0001
    DHGE0.6 ± 2.23.2 ± 220.9 ± 3.13.6 ± 120.100.001−0.060.500.240.002
  • *Comparing interindividually logged isoflavone values with percentage of ideally consumed soy protein doses (bars or protein packages) determined at each specimen collection visit; r, Pearson correlations; P, t test value; 653 PL, 618 OU, and 643 SU data pairs in the placebo group from 146 subjects; 721 PL, 673 OU, and 714 SU data pairs in the soy group from 154 subjects.

  • Wilcoxon rank sum test comparing placebo to soy group.

  • PL mean ± SD in nanomole per liter; baseline n = 175 placebo + 175 soy subjects; study end n = 136 placebo + 143 soy subjects.

  • §OU mean ± SD in nanomole per milligram creatinine; baseline n = 172 placebo + 170 soy subjects; study end n = 120 placebo + 126 soy subjects.

  • SU mean ± SD in nanomole per milligram creatinine; baseline n = 174 placebo, 175 active; study end n = 135 placebo, 143 soy subjects.